Cerene Cryotherapy Studied for Adenomyosis at NYU

Channel Medsystems is supporting an investigator-sponsored study testing its Cerene device in women with adenomyosis.

Updated on Nov. 11, 2026 in Health

Bold flat-color editorial illustration of a cross-section of a muscular uterine wall with dense irregular clusters in its inner band and a cool cylindrical probe entering from the side.
Channel Medsystems is backing an NYU Langone study testing its Cerene cryotherapy device as a treatment for adenomyosis, a condition it is not yet approved to treat. AI Illustration. Upload story photo >

Channel Medsystems announced grant support for an investigator-sponsored study of its Cerene Cryotherapy Device in women with MRI-confirmed adenomyosis. NYU Langone Health's study has enrolled its first patients.

Why it matters

The study aims to generate additional clinical evidence for a condition that Cerene is not currently indicated to treat. It does not change Cerene's current FDA-approved indication for heavy menstrual bleeding due to benign causes.

The study will enroll up to 70 women and track them for 12 months after treatment, with assessments at 3, 6 and 12 months. No efficacy outcomes have been reported, as enrollment has only just begun.

The players

Channel Medsystems, Inc.

A privately held medical technology company based in Berkeley, California, which manufactures the Cerene Cryotherapy Device.

NYU Langone Health

A large academic medical center in New York City whose Center for Fibroid Care is conducting the investigator-sponsored study.

The details

NYU Langone Health's Center for Fibroid Care is conducting the study, with Taraneh Shirazian, M.D., as Principal Investigator. Endometrial cryoablation with the Cerene device is being evaluated as a treatment for women with adenomyosis, a condition in which the uterine lining grows into the muscular wall of the uterus.

Timeline

  1. November 11, 2026: Channel Medsystems announced grant support for the study.

  2. End of 2026: Expected completion of patient treatment.

  3. 12 months post-treatment: Participant follow-up period concludes.

Health Landscape

Cerene's approved use is limited to heavy menstrual bleeding from benign causes, so this study tests whether endometrial cryoablation can extend to adenomyosis, a condition that is not currently an FDA-approved indication for the device. Results would determine whether the procedure is evaluated as a treatment option for a broader set of uterine conditions.

Women with adenomyosis are not currently eligible for Cerene treatment outside of research, and the study does not change how the device is used for approved indications. Patients considering treatment options should discuss FDA-approved indications and available evidence with their clinicians.

The takeaway

Adenomyosis is not yet an approved use for Cerene, so participation in this study is the only route to the treatment under evaluation. Readers should weigh the results once they are published before drawing conclusions about efficacy.

Further reading

For more on treatments for women's reproductive conditions, see Women's Health.

More information

Review Cerene device product information and safety information from the manufacturer.

Source note: This article includes information reported by The Manila times.